As the major U.S. stock indices, including the Nasdaq and S&P 500, show signs of recovery after a challenging week, investors are closely monitoring market movements amid concerns such as potential government shutdowns and fluctuating Treasury yields. In this environment, growth companies with high insider ownership stand out as potentially compelling investments due to their alignment of interests between insiders and shareholders, which can be particularly advantageous when navigating uncertain economic landscapes.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 12.6% | 93.2% |
| Niu Technologies (NIU) | 37.2% | 92.8% |
| IREN (IREN) | 11.2% | 66.6% |
| Hippo Holdings (HIPO) | 14.0% | 41.2% |
| Hesai Group (HSAI) | 15.5% | 41.5% |
| FTC Solar (FTCI) | 23.1% | 63% |
| Credo Technology Group Holding (CRDO) | 11.3% | 33% |
| Celsius Holdings (CELH) | 10.8% | 32.6% |
| Atour Lifestyle Holdings (ATAT) | 21.8% | 23.5% |
| Astera Labs (ALAB) | 12.1% | 36.8% |
Let's review some notable picks from our screened stocks.
Fennec Pharmaceuticals (FENC)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Fennec Pharmaceuticals Inc. is a commercial stage biopharmaceutical company based in the United States with a market cap of $251.60 million.
Operations: Fennec Pharmaceuticals Inc. generates revenue primarily from the production and commercialization of PEDMARK, amounting to $33.30 million.
Insider Ownership: 11.5%
Earnings Growth Forecast: 58.2% p.a.
Fennec Pharmaceuticals exhibits significant insider ownership with recent substantial insider buying, indicating confidence in its future prospects. The company reported a decrease in net loss for Q2 2025 compared to the previous year, with revenue of US$9.65 million. Despite current negative equity, Fennec is projected to achieve profitability within three years and outpace market revenue growth at 30.2% annually. Analysts anticipate a potential stock price increase of 54.9%.
- Click to explore a detailed breakdown of our findings in Fennec Pharmaceuticals' earnings growth report.
- Our valuation report unveils the possibility Fennec Pharmaceuticals' shares may be trading at a discount.
Oddity Tech (ODD)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Oddity Tech Ltd. is a consumer tech company that creates digital-first brands for the beauty and wellness sectors globally, with a market cap of approximately $3.40 billion.
Operations: The company generates its revenue primarily through its Personal Products segment, which accounts for $751.85 million.
Insider Ownership: 21.3%
Earnings Growth Forecast: 16.4% p.a.
Oddity Tech demonstrates robust growth potential with earnings projected to grow 16.4% annually, surpassing the US market average. The company's revenue is also expected to outpace the market at 15.9% per year. Recent guidance revisions forecast net revenue between US$799 million and US$804 million for 2025, reflecting upward adjustments from prior estimates. Despite no recent insider trading activity, analysts agree on a potential stock price increase of 20.7%, indicating confidence in future performance.
- Dive into the specifics of Oddity Tech here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, Oddity Tech's share price might be too pessimistic.
Northpointe Bancshares (NPB)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Northpointe Bancshares, Inc. is the bank holding company for Northpointe Bank, offering a range of banking products and services in the United States with a market cap of $615.13 million.
Operations: The company generates revenue through its Retail Banking segment, which accounts for $155.47 million, and its Mortgage Warehouse (MPP) segment, contributing $52.95 million.
Insider Ownership: 34.8%
Earnings Growth Forecast: 22.5% p.a.
Northpointe Bancshares shows strong growth potential, with earnings forecasted to increase 22.5% annually, outpacing the US market. Recent board appointments bring extensive expertise in cybersecurity and financial services, potentially enhancing strategic direction. Despite trading at a significant discount to its estimated fair value and peers, insider activity has shown more selling than buying recently. Earnings for Q2 2025 rose to US$20.34 million from US$13.22 million year-over-year, indicating solid financial performance amidst low net charge-offs of $488,000.
- Get an in-depth perspective on Northpointe Bancshares' performance by reading our analyst estimates report here.
- Our valuation report here indicates Northpointe Bancshares may be undervalued.
Turning Ideas Into Actions
- Click through to start exploring the rest of the 197 Fast Growing US Companies With High Insider Ownership now.
- Looking For Alternative Opportunities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Northpointe Bancshares might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com